Acerus Announces Licensing of NATESTO – Business Wire (press release)
Posted: June 14, 2017 at 10:47 pm
TORONTO--(BUSINESS WIRE)--Acerus Pharmaceuticals Corporation (TSX:ASP) today announced the signing of an agreement granting medac Gesellschaft fr klinische Spezialprparate mbH (medac) the exclusive right to market NATESTO in 15 European countries (Germany, United Kingdom, France, Italy, Czech Republic, Slovakia, Spain, Sweden, Finland, Denmark, Norway, Poland, Austria, Netherland and Belgium). medac is a German pharmaceutical company with business in 80 countries and more than 1,200 employees worldwide.
We are delighted to be partnering with medac for the commercialization of NATESTO in Europe, said Tom Rossi, President and Chief Executive Officer of Acerus. Their extensive reach and commercial expertise within the speciality pharmaceutical sector will be a key advantage as we aim to maximize the full potential of NATESTO. This agreement represents a significant milestone for Acerus as we continue to execute on our strategy of expanding the brands reach on a global scale.
We are very pleased to announce this partnership with Acerus as it enables us to provide patients in Europe with an innovative product and address a medical need, said Dr. Ulrich Kosciessa, Managing Director of medac. NATESTO is an important advance for patients suffering from hypogonadism. Its novel nasal administration and unique safety and efficacy profile represent a clear opportunity to improve patient quality of life and represents a perfect fit to our current portfolio. We look forward to working closely with Acerus as we prepare to file NATESTO for European marketing approval.
Under the terms of the agreement, Acerus will receive a non-refundable upfront fee and regulatory milestone payments upon medac receiving marketing approval in certain countries as well as milestone payments based on achieving sales targets. In total, Acerus is eligible to receive up to 11,500,000 in upfront and milestone payments. Acerus will oversee the manufacturing of NATESTO and, in addition, will receive a supply price for the product. If approved, NATESTO will be the first and only testosterone nasal gel for androgen replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism) in Europe.1
About NATESTO(Testosterone) Nasal Gel
NATESTO is approved and available in Canada for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). NATESTO is a testosterone nasal gel available in a no-touch dispenser with a metered dose pump for reduced transference risk. The recommended starting dose of NATESTO in Canada is 11 mg of testosterone (one actuation per nostril) administered twice daily for a total daily dose of 22 mg, the lowest topical gel testosterone dose approved in Canada. A copy of the NATESTO product monograph can be found at: http://www.aceruspharma.com/English/products-and-pipeline/natesto/default.aspx.
NATESTO is also approved and available in the United States. For further information, specific to the U.S. product dosing and administration, please visit: http://www.NATESTO.com.
About Acerus
Acerus Pharmaceuticals Corporation is a fully-integrated, Canadian specialty pharmaceutical company engaged in the development, manufacture, marketing and distribution of innovative, branded products in Mens and Womens Health. Acerus shares trade on TSX under the symbol ASP. For more information, visit http://www.aceruspharma.com and follow us on Twitter and LinkedIn.
About medac
medac is a privately held, global pharmaceutical company based in Hamburg, Germany, specialising in the diagnosis and treatment of oncological, urological and autoimmune diseases since 1970. Besides an already established product portfolio medac is dedicated to the refining of existing and the development of new therapeutic products providing patients with ground-breaking individualized treatments. medac prides itself in taking a personalized approach to medicine by supporting doctors and patients as they seek to overcome acute and persistent diseases.
Notice regarding forward-looking statements
Information in this press release that is not current or historical factual information may constitute forward-looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, including with respect to the regulatory approval of NATESTO in Europe and the achievement of the milestone payments by Acerus, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 7, 2017 that is available at http://www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.
References
1. NATESTO Product Monograph, October 25th, 2016 and Rogol et al. J Andrology 2015, 4(1), 46.
Read the original:
Acerus Announces Licensing of NATESTO - Business Wire (press release)
- Testosterone Treatment and Fractures in Men with Hypogonadism | NEJM - nejm.org - January 20th, 2024
- Understanding Hypogonadism, Testosterone Replacement Therapy, and Prostate Cancer Risk - Medriva - January 11th, 2024
- Male hypogonadism - Patient Information - January 3rd, 2024
- Testosterone replacement therapy may not increase risk of prostate cancer among men with hypogonadism - Medical Dialogues - January 3rd, 2024
- Male Hypogonadism Market Expected to Reach $5.1 Billion by 2030 | Current Trends and Industry Analysis - EIN News - December 16th, 2023
- Hypogonadism: What Is It, Causes, Signs and Symptoms, and More - Osmosis - November 2nd, 2023
- Hypogonadism - StatPearls - NCBI Bookshelf - February 10th, 2023
- Male hypogonadism: Symptoms and treatment - PMC - PubMed Central (PMC) - February 10th, 2023
- The 'male menopause' - NHS - November 26th, 2022
- Diagnosis of Hypogonadism: Clinical Assessments and Laboratory Tests - November 1st, 2022
- Approach to the Patient With Hypogonadotropic Hypogonadism - November 1st, 2022
- Clomiphene citrate for men with hypogonadism: a systematic ... - PubMed - September 21st, 2022
- Hypogonadism in females | DermNet - September 21st, 2022
- Clomiphene citrate effects on testosterone/estrogen ratio in male ... - September 21st, 2022
- Male Hypogonadism Market Size to Grow by USD 684.95 Mn, AbbVie Inc. and Bayer AG Among Key Vendors - Technavio - Longview News-Journal - September 21st, 2022
- Male sexual health and reproductive medicine: All that glitters is not gold - Urology Times - September 21st, 2022
- The Reproductive Outcome of Women with HH in IVF - Physician's Weekly - August 20th, 2022
- Men's Health Market is Slated to Witness Tremendous Growth in Coming Years | Latest Report by IBI - Digital Journal - August 20th, 2022
- Why Can Some Medicines Increase The Risk Of Osteoporosis? - Nation World News - August 20th, 2022
- What is Erectile dysfunction (aka ED)? : Buy Kamagra to treat the ED - My MMA News.com - August 20th, 2022
- Sure Signs Your Endocrine System Isn't as Strong as it Should Be Eat This Not That - Eat This, Not That - August 11th, 2022
- What has the NFL said about Packers QB Rodgers consuming ayahuasca? - AS USA - August 11th, 2022
- Male hypogonadism: Symptoms, causes, and treatment - Medical News Today - July 8th, 2022
- Hypogonadism in Men | Endocrine Society - July 8th, 2022
- Olfactory Radioanatomical Findings in Patients With Cardiac Arrhythmias, COVID-19, and Healthy Controls - Cureus - July 8th, 2022
- Global Hormone Replacement Therapy Market Is Projected To Thriving At A CAGR of 1.51% During 2022-2028 | 120 Report Pages - Digital Journal - July 8th, 2022
- Testosterone May Aid Memory in Men With Uncontrolled Diabetes - Everyday Health - June 28th, 2022
- Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer Patients: A Systematic Review - Cureus - June 28th, 2022
- EffRx Pharmaceuticals Signs Exclusive License Agreement With Diurnal for the Registration and Commercialization of Efmody in Switzerland - Business... - April 28th, 2022
- Tucker Carlson hawks testicle tanning to boost testosterone. Experts say it may do the opposite - Salon - April 28th, 2022
- A practical guide to male hypogonadism in the primary care ... - January 1st, 2022
- Waist Circumference Is More Closely Associated with Hypogonadism than Is Hyperglycemia, Independent of BMI in Middle-Aged Men - DocWire News - January 1st, 2022
- Andrological aspects of new coronavirus infection Covid-19 - DocWire News - January 1st, 2022
- Reviewing the Top 5 Best Male Enhancement Pills in 2022 to Buy - The Daily World - January 1st, 2022
- Low Sex Drive (Hypogonadism): Symptoms, Treatment - December 22nd, 2021
- Androgen Deprivation Therapy and the Risk for Inguinal Hernia: An Observational Nested Case Control Study - DocWire News - December 22nd, 2021
- 5 Best Testosterone Boosters to Increase Testosterone Levels in 2022 - Us Weekly - December 22nd, 2021
- Male hypogonadism | You and Your Hormones from the Society ... - November 21st, 2021
- Low testosterone predicts hypoxemic respiratory insufficiency and mortality in patients with COVID-19 disease: another piece in the COVID puzzle -... - November 21st, 2021
- CLARUS THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q) -... - November 21st, 2021
- Bio-Identical Hormone Replacement Therapy Market to Rise Due to the Increasing Applications and Wider Reach, Players Pfizer Bayer. Energy Siren -... - November 21st, 2021
- Hormone Replacement Therapy Market Rise in Sustainability Around The World 2021 2030 - Taiwan News - October 5th, 2021
- 6 Things To Look for In a Good Testosterone Booster Supplement - The Portugal News - October 5th, 2021
- Androgen Deprivation Therapy, Hypogonadism and Cardiovascular Toxicity in Men with Advanced Prostate Cancer - DocWire News - October 5th, 2021
- [PDF] Hormone Replacement Therapy Market to Reflect Steady Growth and Future Scope UNLV The Rebel Yell - UNLV The Rebel Yell - August 30th, 2021
- Top 6 Benefits of Testosterone Therapy Times Square Chronicles - Times Square Chronicles - August 3rd, 2021
- Hormone Replacement Therapy Market by 2027 Worldwide Growth Opportunities Recent Trends Forecast by Types and Application to 2027 The Manomet Current... - August 3rd, 2021
- 9 Ways to Increase Testosterone Naturally in 2021 - Men's Journal - August 3rd, 2021
- Testosterone Therapy for Hypogonadism Guideline Resources ... - May 26th, 2021
- Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And... - May 26th, 2021
- Trending Report of Male Hypogonadism Market Drivers, Strategies, Applications and Competitive Landscape 2026 Brockville Observer - Brockville... - May 26th, 2021
- Male menopause: Here's everything you need to know about andropause - Pulse Ghana - May 26th, 2021
- Blue Water Acquisition : Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory... - May 26th, 2021
- Hormone Replacement Therapy Market Size to Surpass US$ 36.54 Billion by 2027 with the CAGR of 8.20% The Manomet Current - The Manomet Current - May 26th, 2021
- The many effects of reproductive hormones on the brain - ESHRE - May 26th, 2021
- Hormone Replacement Therapy (HRT) Market to Eyewitness Stunning Growth by 2027 Covid-19 Analysis The Shotcaller - The Shotcaller - May 26th, 2021
- The Male Hypogonadism Market To Witness Steadfast Growth In The Next 10 Years The Courier - The Courier - May 14th, 2021
- The Male Hypogonadism Market To Ride On Innovations KSU | The Sentinel Newspaper - KSU | The Sentinel Newspaper - May 14th, 2021
- Hormone Replacement Therapy Market Global Industry Scope and Growth Analysis Report 2021: Opportunity Assessment, Business Boosting Strategies, and... - May 14th, 2021
- Global Hormone Replacement Therapy (HRT) Industry Market Report 2020, Forecast Till 2027 By Type, End-use, Geography and Player The Courier - The... - May 14th, 2021
- Immunosenescence Profile and Expression of the Aging Biomarker (p16INK4a) in Testicular Cancer Survivors Tr... - UroToday - February 11th, 2021
- Europe to hold The major Piece of Cake in the Anabolic Steroids Market between 2020 and 2030 Jumbo News - Jumbo News - February 11th, 2021
- The Male Hypogonadism Market to witness a splendid CAGR in the next decade Murphy's Hockey Law - Murphy's Hockey Law - February 3rd, 2021
- Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Pha... - UroToday - February 3rd, 2021
- Marius Pharmaceuticals Announces Co-CEOs Himanshu H. Shah and Shalin Shah to Drive Growth ahead of Anticipated FDA Action of its Lead Asset, KYZATREX... - January 29th, 2021
- Male Hormone Replacement Therapy And The Side Effects - Nerd's Magazine - January 29th, 2021
- New York Medical and Life Sciences: Year in Review 2020 - JD Supra - January 29th, 2021
- Male menopause: symptoms, diagnosis and treatment - Netdoctor - January 29th, 2021
- Freeman: 'Pressure to Succeed' Led to Testosterone Order - Medscape - January 27th, 2021
- Hormone Replacement Therapy Market Growth Analysis,Size,Insight,Share And Outlook By 2027 Pfizer, AbbVie, Novo Nordisk NeighborWebSJ - NeighborWebSJ - January 27th, 2021
- Male Hypogonadism Therapy Market to Witness Massive Growth During 2021-2027 | Eli Lilly, Pfizer, AbbVie, Novo Nordisk, Merck KGaA, Mylan, Bayer, Teva,... - January 25th, 2021
- Male Hypogonadism Therapy Market and Ecosystem by Production, Prospects, Consumption, Cost Structure, Competitive Landscape - Jumbo News - January 25th, 2021
- What is Harvey Prices disability Prader-Willi Syndrome? - The Sun - January 25th, 2021
- The Male Hypogonadism Market To Witness An Escalating CAGR Of 3.7% - NeighborWebSJ - January 19th, 2021
- Androgen Replacement Therapy Market to Witness Robust Expansion throughout the Forecast Period 2017-2026 | AbbVie, Inc., Allergan Plc, Bayer AG, Endo... - January 19th, 2021
- Global COVID-19 Diagnostics Market Size Worth USD 11.40 Billion at 7.9% CAGR; Pharmaceutical Giants Such as Abbott and Roche to Pump More Funds for... - January 19th, 2021
- Marius Pharmaceuticals Submits New Drug Application to US FDA for Next-Generation Oral Testosterone Replacement Therapy in Male Patients With... - January 12th, 2021
- Testosterone Replacement Therapy Market (2020 2027) Explosive Factors of Revenue by Key Manufacturer, Share, Future Trends, COVID-19 Market Scenario,... - January 9th, 2021
- The Anabolic Steroids Market to sharpen in the next decade - The Monitor - January 9th, 2021
- Brief Report Treatment of infertility and menopause in a patient with multiple sclerosis affecting the pituitary stalk: a case report - DocWire News - December 24th, 2020